Filter by:
Rejuva
ObesityWeek, 2024
Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves Metabolism in Obese Mice
Rajagopalan, et al, presented at The Obesity Society’s Annual Meeting at ObesityWeek 2024
Revita
ObesityWeek, 2024
Duodenal Mucosal Resurfacing Durably Maintains Weight Loss in Metabolic Disease
White, et al, presented at The Obesity Society’s Annual Meeting at ObesityWeek 2024
Revita
DGVS, 2024
A prospective post-market clinical follow-up registry to evaluate real-world effectiveness and patient satisfaction after duodenal mucosal resurfacing in patients with type 2 diabetes
Beyna, et al, presented at Visceral Medicine 2024 Meeting of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS)
Rejuva
ADA, 2024
Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia After Semaglutide Withdrawal in a Murine Model of Obesity
Rajagopalan, et al, presented at the American Diabetes Association’s 84th Scientific Sessions
Rejuva
DDW, 2024
Single-dose GLP-1-based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal and Reduces Hepatic Triglycerides in a Murine Model of Obesity
Rajagopalan, et al, presented at Digestive Disease Week, Washington, D.C., May 2024
Revita
DDG, 2024
A Prospective Post-market Clinical Follow-up Registry to Evaluate Real-world Effectiveness of Duodenal Mucosal Resurfacing in Patients with Type 2 Diabetes
Martin, et al, presented poster at German Diabetes Association (DDG) Annual Meeting, 2024, Berlin, Germany, May 2024
Revita
WIley
A Look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes
Jonah A. Hoyt, et al
Revita
Gastrointest Endosc
Insulin Sensitivity and Beta Cell Function After Duodenal Mucosal Resurfacing (DMR): An Open-Label, Mechanistic, Pilot Study
Celine B E Busch, et al
Revita
Diabetes Res Clin Pract.
Bariatrics and Endoscopic Therapies for the Treatment of Metabolic Disease: Past, Present, and Future
Geltrude Mingrone, et al